Therapeutic application of Kazal-type serine protease inhibitors

US8283319B2 · kind B2 · utility

Assignee

• CSL Behring AG · DE

Inventors

• Stefan Schulte · Marburg, DE
• Ulrich Kronthaler · Deisenhofen, DE
• Stefan Schmidbauer · Lahntal, DE
• Thomas Weimer · Gladenbach, DE
• Kay Hofmann

Key dates

• Filing date: Feb 11, 2008
• Grant date: Oct 9, 2012
• Expiry date: Mar 17, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the therapeutic application of the Kazal-type serine protease inhibitor Infestin or domains thereof or modified Kazal-type serine protease inhibitors based on Infestin homologs, which prevent the formation and/or stabilization of three-dimensional arterial or venous thrombi by interfering with proteins involved in activation of the so-called intrinsic coagulation pathway. The present invention also relates to the use of Kazal-type serine protease inhibitors or fragments thereof or modified Kazal-type serine protease inhibitors in the treatment or prophylaxis of a condition or disorder related to arterial thrombus formation, i.e. stroke or myocardial infarction, inflammation, complement activation, fibrinolysis, angiogenesis and/or diseases linked to pathological kinin formation such as hypotonic shock, edema including hereditary angioedema, bacterial infections, arthritis, pancreatitis, or articular gout, Disseminated Intravasal Coagulation (DIC) and sepsis.